Rutao Wang1,2,3,4, MD; Chao Gao1,2,3,4, MD; Hideyuki Kawashima1,2,5, MD; Rodrigo Modolo6, MD; Liesbeth Rosseel1,2, MD; Yoshinobu Onuma1,2, MD, PhD; Osama Soliman1,2, MD, PhD; Patrick W. Serruys1,2,7, MD, PhD; Darren Mylotte1,2, MBBCh, MD, PhD
1. Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland; 2. Department of Cardiology, Xijing Hospital, Xi’an, China; 3. Department of Cardiology, Radboud University, Nijmegen, the Netherlands; 4. CORRIB Research Center for Advanced Imaging and Core Lab, Galway, Ireland; 5. Department of Cardiology, Amsterdam University Medical Center, Amsterdam, the Netherlands; 6. Department of Internal Medicine, Cardiology Division, University of Campinas (UNICAMP), Campinas, SP, Brazil; 7. NHLI, Imperial College London, London, United Kingdom
Percutaneous valve technologies have revolutionised the treatment of valvular heart disease (VHD) and emerged as an alternative treatment option in elderly patients at all levels of surgical risk. In 2019 and 2020, important advances in the field of valvular heart interventions were achieved. In this review, we present the most recent and relevant studies that have emerged on the transcatheter treatment of VHD in 2019 and 2020.
In August 2019, the U.S. Food and Drug Administration (FDA) approved the use of transcatheter aortic valve replacement (TAVR) for the treatment of symptomatic severe aortic stenosis (AS) in low-risk ...
No account yet? Create my pcr account
Sign up for free!
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases
aortic stenosismitral regurgitationparavalvular leaktavitricuspid diseasettvr
Interventions for valvular diseaseTAVIMitral valve replacement and repairTricuspid / Pulmonary valve
Read next article
Transcatheter edge-to-edge mitral valve repair with the PASCAL system: early results from a real-world series